| Autor: |
Moul JW; Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA., Sant GR; Department of Urology, Tufts University School of Medicine, Boston, Massachusetts, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
The Canadian journal of urology [Can J Urol] 2022 Aug; Vol. 29 (4), pp. 11224-11230. |
| Abstrakt: |
Prostate-specific antigen (PSA) screening remains the mainstay for early detection of prostate cancer. Although PSA is a nonspecific prostate cancer biomarker, its specificity for high grade prostate cancer can be enhanced by pre-biopsy liquid biomarkers including the Exosome Dx Prostate IntelliScore (EPI) test. EPI is a stand-alone urine genomic test that measures 3 exosome-derived gene expression signatures without the need for digital rectal examination (DRE) or inclusion of standard of care parameters in the test algorithm. EPI has broad clinical utility as a risk stratification tool for clinically significant high grade prostate cancer in men considering diagnostic prostate biopsy (MRI-targeted and systematic biopsy). During the COVID-19 pandemic, the EPI At-Home Collection Kit was introduced and quickly became an important component of tele-urology. The EPI test has emerged as a prioritization tool for primary care referral to urologists and for prostate biopsy scheduling. EPI provides an objective and actionable genomic risk assessment tool for high grade prostate cancer and is a critical part of the informed decision-making regarding biopsy (targeted, systematic or both) in both urology and primary care practices. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
